-
AI in Healthcare: The Impact of DeepSeek Technology and Industry Developments
•
The integration of advanced AI technologies into healthcare is revolutionizing the industry, and the recent developments involving DeepSeek technology have further amplified this transformation. As highlighted by policy updates and industry trends, AI-powered solutions are gaining momentum across various sectors of healthcare, from diagnostics to drug discovery. This article explores…
-
In-Depth Analysis of the National Healthcare Security Policy: A Guide to Key Reforms and Implications
•
The National Healthcare Security Administration (NHSA) has unveiled its 2025 priority action list, focusing on improving efficiency and accessibility in healthcare services. This policy reform targets three key stakeholders: designated medical institutions, pharmaceutical companies, and insured individuals, introducing six major service initiatives. Below is a detailed analysis of the reforms,…
-
State Council’s Draft Plan Boosts Innovative Drug Development via Medical Insurance Reforms
•
The State Council has released a second draft proposal outlining measures to support the high-quality development of innovative drugs through medical insurance reforms. The document emphasizes the establishment of innovative drug investment funds, self-assessment mechanisms for drug pricing, and enhanced real-world research support. Key Proposals NRDL and Drug ListingThe draft…
-
Roche Unveils Sequencing by Expansion (SBX) Technology for Next-Generation Sequencing
•
Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced the presentation of its proprietary sequencing by expansion (SBX) technology, marking a significant advancement in next-generation sequencing (NGS). Technology OverviewSBX integrates innovative sensor modules to provide ultra-fast and high-throughput sequencing solutions. The technology is designed with broad flexibility and scalability, making…
-
Shanghai Issues Legal Guidebook for Innovative Drug Marketing
•
The Shanghai Municipal Market Supervision Administration Bureau has delivered a legal guidebook tailored for innovative drug marketing to pharmaceutical companies. The guidebook provides recommendations on commercial promotion, academic exchanges, transparent pricing, distributor management, and risk prevention. Key Provisions BackgroundThe guidebook was developed following a July 2024 research visit by the…
-
China Outlines Drug Pricing Reforms, Encourages Insurance Funds for Innovation
•
The Chinese government has released a set of opinions detailing the establishment of a new drug price formation mechanism by 2027, aiming to reduce financing costs for the innovative drug industry and support pharmaceutical innovation. Insurance Fund RoleThe document encourages commercial insurance companies to establish or clarify existing investment funds…
-
Roche’s Tecentriq Wins Japan Approval for Alveolar Soft Part Sarcoma
•
Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) and its Japanese partner Chugai Pharmaceutical Co., Ltd. (TYO: 4519) announced that the Ministry of Health, Labour and Welfare of Japan has approved Tecentriq (atezolizumab) for the treatment of unresectable alveolar soft part sarcoma. This marks the first approval of an immune…
-
GSK’s Nucala Receives NMPA Review for COPD Treatment
•
GSK plc (LON: GSK, NYSE: GSK) announced that the National Medical Products Administration (NMPA) has accepted another indication approval filing for its anti-interleukin-15 (IL-15) biologic Nucala (mepolizumab) for review. The UK-based company is seeking approval for the drug’s use as an add-on maintenance treatment for patients with chronic obstructive pulmonary…
-
Nuwacell Biotech’s NCR101 Approved for ILD Clinical Study by China’s CDE
•
According to the Center for Drug Evaluation (CDE) website, China-based Nuwacell Biotechnology Co., Ltd. has obtained approval for its NCR101 to conduct clinical trials in interstitial lung disease (ILD). Drug ProfileNCR101 is an induced pluripotent stem cell (iPSC)-derived mesenchymal-like cells (MSCs) therapy. The product has achieved large-scale production and ensures…
-
Baxter International Reports Q4 2024 Revenues of USD 2.75B, Up 2% YOY
•
Baxter International (NYSE: BAX) announced its fourth-quarter 2024 financial results, reporting revenues of USD 2.75 billion, a 2% increase year-on-year (YOY). For the full year, revenues rose 3% YOY to USD 10.64 billion. Q4 Segment Performance Full-Year Segment Performance Kidney Care BusinessBaxter completed the sale of its Kidney Care business…
-
Horimed Raises USD 13.8M to Advance Optical and Ultrasonic Imaging Tech
•
Horimed, a Tianjin-based medical device firm specializing in optical and ultrasonic medical imaging technology and laser ablation, has reportedly raised over RMB 100 million (USD 13.8 million) in a new financing round. Investors include Nanjing NII Group, Huatai Zijin, Peiyang Begonia Fund, Andon Health, and bioVenture, with Starboard Value serving…
-
Gene Cradle and Byongen Therapeutics Partner on Next-Generation DMD Gene Therapies
•
Gene Cradle and Byongen Therapeutics, both Beijing-based gene therapy specialists, have formed a strategic alliance to develop next-generation gene therapies for Duchenne muscular dystrophy (DMD). Collaboration FocusGene Cradle, which initiated its DMD gene therapy project in 2021, has focused on optimizing Dystrophin proteins and regulatory elements. The company has designed…
-
Bristol-Myers Squibb’s Opdivo Shows Survival Benefit in CheckMate-816 Study
•
Bristol-Myers Squibb (BMS, NYSE: BMY) announced the final analysis of overall survival (OS) data from the Phase III CheckMate-816 study for its Opdivo (nivolumab) in patients with resectable non-small cell lung cancer (NSCLC). Study HighlightsThe CheckMate-816 study evaluated Opdivo in combination with platinum-doublet chemotherapy as a neoadjuvant treatment for adult…
-
Corxel Pharmaceuticals to Test JX10 in Acute Ischemic Stroke Patients with NMPA Approval
•
China-based Corxel Pharmaceuticals (CORXEL) has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study evaluating the functional recovery of acute ischemic stroke (AIS) patients treated with JX10 within a time window of 4.5 to 24 hours from the “last known well.” Drug ProfileJX10 is an…
-
Harbour BioMed and Insilico Medicine Partner on AI-Powered Antibody Development
•
China-based Harbour BioMed (HKG: 2142) announced a strategic partnership with Insilico Medicine, a generative artificial intelligence (AI)-driven biotech firm. The collaboration aims to leverage their respective strengths in antibody discovery and AI to accelerate the development of innovative therapeutic antibodies. Partnership DetailsThe partnership combines Harbour BioMed’s industry-leading technology platform, proprietary…
-
Gilead’s Livdelzi Receives Conditional EC Approval for Primary Biliary Cholangitis
•
US-based Gilead Sciences Inc. (NASDAQ: GILD) announced that it has received conditional approval from the European Commission (EC) for its liver disease drug Livdelzi (seladelpar). The drug is approved for use in combination with ursodeoxycholic acid (UDCA) to treat primary biliary cholangitis (PBC) in adults who have an inadequate response…
-
FibroGen to Sell China Subsidiary to AstraZeneca for ~$160M, Roxadustat Rights Included
•
US-based biopharma FibroGen Inc. (NASDAQ: FGEN) has entered into an agreement to sell its China subsidiary to UK-based AstraZeneca (NASDAQ: AZN) for approximately USD160 million. The deal includes the transfer of all rights to roxadustat, a treatment for anemia caused by chronic kidney disease (CKD), in China. Transaction DetailsUnder the…
-
Waterdrop Integrates DeepSeek AI to Boost Insurance Ecosystem
•
China-based Waterdrop Inc. (NYSE: WDH), a crowdfunding-based health insurance platform, announced a strategic integration with DeepSeek, a Chinese artificial intelligence (AI) company specializing in large language models (LLMs). This collaboration marks a significant advancement in Waterdrop’s AI-driven insurance ecosystem. Company BackgroundSince its founding in 2016, Waterdrop has focused on promoting…
-
Boehringer Ingelheim Launches LENTICLAIR Study for CF Gene Therapy BI 3720931
•
German pharmaceutical company Boehringer Ingelheim announced the initiation of the Phase I/II LENTICLAIR study for its gene therapy candidate BI 3720931 in cystic fibrosis (CF). The study is being conducted in collaboration with IP Group, the UK Respiratory Gene Therapy Consortium (GTC), and OXB. Study DetailsBI 3720931 is an inhaled…
-
Huadong Medicine’s Biosimilar Tresiba Accepted by NMPA for Review
•
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its market filing for a biosimilar version of Denmark-based Novo Nordisk A/S’s (NYSE: NVO) Tresiba (insulin degludec) has been accepted for review by the National Medical Products Administration (NMPA). The targeted indication is adult type 2 diabetes. Drug ProfileInsulin degludec, a…
